New drug combo aims to control lymphoma without chemo
NCT ID NCT04883437
First seen Feb 16, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This phase 2 trial is testing a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated follicular lymphoma or other slow-growing non-Hodgkin lymphomas. The goal is to see if this drug pair can shrink tumors and control the disease. About 49 participants will receive the drugs, and researchers will monitor how well the cancer responds and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib and obinutuzumab
What this could lead to
If this works, it could offer a new, effective treatment option for people with untreated follicular lymphoma, potentially controlling the disease without chemotherapy.
What could go wrong
This is an early phase 2 trial with only 49 participants. The combination may cause side effects, and it's not yet known if it works better than standard treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.